Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR) filed this Form 8-K on August 13, 2024, regarding a regulatory notice received from The Nasdaq Stock Market LLC. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point provided is the stock price performance triggering the notice: the closing bid price of the Company's common stock has remained below the required minimum of $1.00 per share for the last 32 consecutive business days.
Material Changes
The material change reported is the receipt of a deficiency letter from Nasdaq citing non-compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"). This notice indicates the stock price has failed to meet the $1.00 minimum threshold for 32 consecutive business days.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted 180 calendar days, until February 10, 2025, to regain compliance.
- Compliance Criteria: To cure the deficiency, the closing bid price must reach at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date.
- Secondary Compliance Period: If the Company fails to regain compliance by February 10, 2025, it may be eligible for an additional 180-day period. This requires meeting all other initial listing standards (excluding the bid price) and potentially effecting a reverse stock split.
- Delisting Risk: If the Company cannot cure the deficiency or is ineligible for an extension, Nasdaq may issue a delisting notification. The Company may appeal this determination, though success is not assured.
- Management Action: Management intends to monitor the stock price and consider available options, including a reverse stock split, to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of XFOR stock relative to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes.
- Track the stock price performance over the next 10 consecutive business days to assess immediate compliance progress.
- Review future filings for updates on the February 10, 2025, compliance deadline.